黛力新与丙咪嗪治疗脑卒中后抑郁症的疗效比较

Deanxit and imipramine in the treatment of post-stroke depression compared

目的比较黛力新和丙咪嗪治疗脑卒中后抑郁症(PSD)的疗效及安全性。方法将90例PSD患者随机分为对照组(丙咪嗪治疗)44例和治疗组(黛力新治疗)46例,在治疗前和治疗4周后行汉密尔顿抑郁量表(HAMD)评分,进行疗效评定,并观察不良反应。结果两组临床疗效比较,治疗组的总有效率与对照组比较差异有显著意义(P<0.05);治疗组的HAMD评分与对照组比较差异有显著意义(P<0.05),治疗组的不良反应发生率与对照组比较差异有显著意义(P<0.05)。结论黛力新治疗脑卒中后抑郁症疗效优于丙咪嗪,且不良反应较少。

Objective To compare the deanxit and imipramine in the treatment of post-stroke depression （PSD） of the efficacy and safety.Methods 90 cases of PSD were randomly divided into control group （imipramine in the treatment） and 44 cases of treatment group （treatment deanxit） 46 patients before treatment and treatment in the four weeks later,Hamilton Depression Rating Scale （HAMD） score to assess its efficacy,and adverse reactions observed.Results Comparison of clinical efficacy results of two groups,treatment group the total effective rate compared with the control group the difference was significant （P〈0.05）;treatment group HAMD score compared with the control group the difference was significant （P〈0.05）,treatment group,the adverse reaction rates compared with the control group the difference was significant （P〈0.05）.Conclusion Deanxit treatment of post-stroke depression more effective than imipramine,and less adverse reactions.